What happened, in summary

Bekah Cunningham was 29 when months of coughing up blood and repeated respiratory infections led to a life-changing diagnosis. A breast lump was initially thought to be Stage II triple-negative breast cancer, but further testing showed that the lump had spread from her lung. Her final diagnosis was Stage IV lung cancer. Molecular testing then identified ALK-positive disease, opening the door to targeted treatment. After an earlier medication, Bekah switched to alectinib. The drug caused muscle discomfort, a widespread rash, and sensitivity to sunlight at first, but those effects gradually became easier to manage. As her health improved, Bekah rebuilt her life around travel, work, and physical activity. In 2019, she completed the roughly 2,200-mile Appalachian Trail, taking the hike slowly as her strength returned. She continued regular follow-up at Dana-Farber, and maintenance scans remained clear 6 years after she started alectinib. Bekah describes not simply living with Stage IV lung cancer, but continuing to thrive while on long-term targeted therapy.